Darizmetinib

CAS No. 2369583-33-3

Darizmetinib( —— )

Catalog No. M36482 CAS No. 2369583-33-3

Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 151 In Stock
2MG 91 In Stock
5MG 150 In Stock
10MG 236 In Stock
25MG 342 In Stock
50MG 414 In Stock
100MG 606 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Darizmetinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
  • Description
    Darizmetinib is an inhibitor of mitogen-activated protein kinase kinase (MAP2K).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    p38 MAPK
  • Recptor
    MAPK | Antiviral
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2369583-33-3
  • Formula Weight
    457.45
  • Molecular Formula
    C21H17F2N5O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(C1=NNC2=NC=C(C=C21)C=3C=CN=CC3)C4=CC=C(F)C(NS(=O)(=O)CCC)=C4F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Praefke B, et al. Preparation of pyrazolopyridines as protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death: World Intellectual Property Organization, WO2019149738. 2019-08-08.
molnova catalog
related products
  • p38α inhibitor 4

    p38α inhibitor 4 is a selective MAPK p38α inhibitor, which is used to study diabetes, pain and chronic inflammation.

  • LY2228820 dimesylate

    LY2228820 dimesylate (Ralimetinib) is a potent, selective, orally available inhibitor p38 MAPK with IC50 of 5.3 and 3.2 nM for p38α and p38β, respectively.

  • 16,17-Epoxypregnenol

    16,17-Epoxypregnenol